Value through Innovation02 August 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

back 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
23.07.2014

Pradaxa® (dabigatran etexilate) Video Statement

- For media outside UK, U.S. and Canada
23.07.2014

Efficacy and Safety Profile of Pradaxa® (dabigatran etexilate) Repeatedly Confirmed

- For media outside UK, U.S. and Canada
22.07.2014

Boehringer Ingelheim Establishes a Research Alliance with the University of Toronto, the Toronto-based University Health Network and the Mount Sinai Hospital to investigate new therapeutic concepts in the field of ubiquitin signalling biology

16.07.2014

Boehringer Ingelheim’s investigational therapy nintedanib* receives the first FDA breakthrough therapy designation in IPF

- For non-US media only
08.07.2014

Boehringer Ingelheim’s volasertib showed in a Phase II study an improvement in overall survival in older AML patients

- For media outside of the US/UK only
07.07.2014

Judit Makara wins Boehringer Ingelheim’s FENS Award 2014 for Exceptional Research in Neuroscience

- For Non-US, Non-UK Media Only
30.06.2014

U.S. FDA grants Breakthrough Therapy Designation to Pradaxa® (dabigatran etexilate) specific investigational antidote

- For media outside of the U.S., the UK & Canada only
27.06.2014

CHMP Recommends Lilly and Boehringer Ingelheim’s New Insulin Glargine Product for Approval in the European Union

- For Non-U.S. and Non-U.K. Media
20.06.2014

Boehringer Ingelheim Statement on Hepatitis C drug development

- For media outside of the US, the UK only
20.06.2014

New Pradaxa® clinical study to explore practical management of patients with atrial fibrillation undergoing ablation

- For media outside of the U.S., the UK & Canada only
16.06.2014

Type 2 Diabetes: Jardiance® (empagliflozin) as an add-on therapy significantly reduced blood glucose and body weight in two newly presented Phase III trials

- For Non-U.S. and Non-U.K. Media
16.06.2014

New survey in five European countries reveals urgent need to improve education about Acute Myeloid Leukaemia

- For media outside of the US/UK only
15.06.2014

Type 2 Diabetes: Physicians worldwide agree early conversations are crucial in the management of condition

- For Non-US and Non-UK Media
14.06.2014

Studies Show Investigational New Insulin Glargine Product from Lilly and Boehringer Ingelheim Similar in Safety and Efficacy to Lantus®

- For Non-U.S. and Non-UK Media
10.06.2014

Diabetes: Boehringer Ingelheim and Eli Lilly and Company Alliance to have 43 Presentations Featured at the American Diabetes Association’s 74th Scientific Sessions®

- For Non-US and Non-UK Media
06.06.2014

Pradaxa® gains EU approval for treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism

- For media outside of the U.S., the UK & Cananda only
05.06.2014

EMA accepts marketing authorisation application for nintedanib* in IPF

- For non-US health media only
03.06.2014

Boehringer Ingelheim Announces Successful Resolution of FDA Warning Letter

back 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16